Have a personal or library account? Click to login
Presence of nitrosamine impurities in medicinal products Cover

Presence of nitrosamine impurities in medicinal products

Open Access
|Mar 2021

Figures & Tables

Figure 1

Production changes that caused formation of NDMA in the Zhejiang Huahai Pharmaceutical plant (6)
Production changes that caused formation of NDMA in the Zhejiang Huahai Pharmaceutical plant (6)

Figure 2

Sartans with a tetrazole ring contaminated with impurities (4)
Sartans with a tetrazole ring contaminated with impurities (4)

The most common sources of NDMA and NDEA impurities in medicinal products (3, 4, 6)_

Sources of nitrosamine contamination/formation in the API
Critical combinations of compoundsNitrosamineNOx sourceAmine sourceAmine nitrosated by NOxCritical combination
NDMANaNO2Dimethylformamide (DMF)Dimethylamine (DMA)reagent / solvent
NDEANaNO2Triethylamine (TEA)Diethylamine (DEA)reagent / reagent
Triethylamine hydrochloride (TEA HCl)Triethylamine (TEA)reagent / catalyst
Reagents, solvents, and catalystsThe use of azide reagents in the synthesis of tetrazole, under the acidic conditions required for the isolation and extraction of tetrazole, releases the dangerous hydrazoic acid which can give e.g. amines. The remaining amounts of azide can be decomposed into gaseous by-products such as nitrogen and nitrous oxide (N2O) by the addition of sodium nitrite (NaNO2).
Faults in the production processInappropriate or poorly controlled reaction conditions concerning temperature, pH, or the order of addition of reagents, intermediates, or solvents.
Recovered and recycled materialsIf the solvents used in the reaction step involving azide are collected and reused, there is a possibility that nitrosamines may be inadvertently introduced into the production process if the waste stream is quenched with nitrite in the presence of secondary or tertiary amines and subsequently treated with nitric acid, e.g. to destroy residual azides without adequate process control. There is also a possibility that the process water used in the production of the API may contain low levels of nitrosamines due to environmental pollution.
Third-partyExternal recovery companies do not receive sufficiently specific information on the composition of the materials they process and they use routine processing procedures and generally accepted equipment. This can lead to cross-contamination of solvents, reagents, and catalysts (originating from different sources and processes) if the equipment is not properly cleaned between customer orders or if precautions are not taken to prevent the formation of nitrosamines.
Contaminated raw materials and intermediatesDistributors using recovered materials or raw materials that contain nitrites or amines and whose processing can lead to the formation of nitrosamines. Problematic if an API manufacturer who exclusively uses nitrosamine-free processes is not aware that there is a risk of nitrosamine formation.
DOI: https://doi.org/10.2478/aiht-2021-72-3491 | Journal eISSN: 1848-6312 | Journal ISSN: 0004-1254
Language: English, Croatian, Slovenian
Page range: 1 - 5
Submitted on: Sep 1, 2020
Accepted on: Mar 1, 2021
Published on: Mar 30, 2021
Published by: Institute for Medical Research and Occupational Health
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2021 Ilijana Sedlo, Teo Kolonić, Siniša Tomić, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.